Orphazyme A/S (ORPH)

$ 9.33
-11.67 (-55.57%)
-
Symbol ORPH
Price $ 9.33
Beta 0.813
Volume Avg. 0.85M
Market Cap 0.46B
Shares () -
52 Week Range 4.75-77.77
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -138.24% Strong Sell
ROA -59.01% Strong Sell
Operating Margin -
Debt / Equity 32.55% Neutral
P/E -
P/B 1.90 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

ORPH Stock Price: Over 50% Decrease Pre-Market Explanation

ORPH Stock Price: Over 50% Decrease Pre-Market Explanation

The stock price of Orphazyme A/S (NASDAQ: ORPH) fell by over 50% pre-market. These are the details. ...

Pulse2
Why Did Orphazyme (ORPH) Shares Skyrocket As Much As 1387% Today?

Why Did Orphazyme (ORPH) Shares Skyrocket As Much As 1387% Today?

Orphazyme A/S (NASDAQ: ORPH) shares skyrocketed over 300% in the regular session on Thursday. What Happened: Shares of the Denmark-based biopharmaceutical firm touched an intraday high of $77.77, running up 1,387%. ...

Benzinga
Orphazyme Stock: 7 Things to Know About ORPH as Shares Skyrocket

Orphazyme Stock: 7 Things to Know About ORPH as Shares Skyrocket

Today, Orphazyme stock is on the move and is trading with extremely heavy volume, as momentum traders drive up the value of this small cap. The post Orphazyme Stock: 7 Things to Know About ORPH as Shares Skyrocket appeared first on InvestorPlace. ...

InvestorPlace
ORPH Stock Price: Over 1,386% Increase Explanation

ORPH Stock Price: Over 1,386% Increase Explanation

The stock price of Orphazyme (NASDAQ: ORPH) increased by over 1,386% during intraday trading. This is why it happened. ...

Pulse2
Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times

Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times

Shares of Orphazyme A/S blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intr... ...

Market Watch
What Are Penny Stocks? 4 to Buy [Or Sell] In 2021

What Are Penny Stocks? 4 to Buy [Or Sell] In 2021

Wondering what penny stocks are? Here's your answer and 4 to watch The post What Are Penny Stocks? ...

PennyStocks
ORPH Stock: Is There a Big Orphazyme Catalyst on June 17?

ORPH Stock: Is There a Big Orphazyme Catalyst on June 17?

Today, ORPH stock is on the move, on what appears to be no real catalysts as momentum traders pile into this small cap stock. The post ORPH Stock: Is There a Big Orphazyme Catalyst on June 17? ...

InvestorPlace
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orphazyme A/S - ORPH

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orphazyme A/S - ...

NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH).  Such investors are advised to contact Robert S. ...

PRNewsWire
CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: OR... ...

Business Wire
CytRx Notes Orphazyme's Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis

CytRx Notes Orphazyme's Announcement of Topline Results from Trial for Arimoclomol in the Treatment ...

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: OR... ...

Business Wire

About


Ms. Kim Stratton
Healthcare
Biotechnology
NMS

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.